0001822359 false 0001822359 2022-11-06 2022-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549










Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): November 6, 2022



(Exact name of registrant as specified in its charter)


Delaware   001-39618   85-2515483
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)


35 West 35th Street, Floor 6, New York, New York
(Address of principal executive offices)
(Zip Code)


(844) 443-6246

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class  




Name of each exchange on

which registered

Common stock, par value $0.0001 per share   DCGO   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.







Item 2.02 Results of Operations and Financial Condition.


 On November 7, 2022, DocGo Inc. (the “Company”) issued a press release that announced earnings results for the quarter ended September 30, 2022. The press release also announces the decision of Stan Vashovsky, the Company’s Chief Executive Officer and Chairman, to retire from the Company, effective as of December 31, 2022, as discussed in Item 5.02 below. This press release is furnished as Exhibit 99.1 to this report.


The information in Item 2.02 of this report and the exhibit attached hereto is being furnished and shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On November 6, 2022, Stan Vashovsky notified the Board of Directors of the Company (the “Board”) that he intends to retire from the Company and step down as the Company’s Chief Executive Officer, director and Chairman of the Board, effective as of December 31, 2022 (the “Effective Time”). In connection with Mr. Vashovsky’s retirement, the Board appointed Anthony Capone, the Company’s current President, to succeed Mr. Vashovsky as the Chief Executive Officer of the Company, effective upon the Effective Time. Mr. Capone will no longer serve as the Company’s President as of such time. Mr. Vashovsky will continue to consult with the Company through 2023 pursuant to a transition agreement expected to be entered between Mr. Vashovsky and the Company, the terms of which agreement shall be disclosed following such time.


Mr. Capone, age 35, has served as the Company’s President since November 2021. Mr. Capone previously held various positions at Ambulnz, Inc. between 2017 and 2021, including those of President, Chief Technology Officer and Chief Product Officer. Prior to Ambulnz, Mr. Capone served as the Chief Executive Officer, Chief Technology Officer and Head of Sales at Fundbase, an investment platform, from 2015 to 2017. From 2011 to 2013, Mr. Capone served as the lead software engineer at Constant Contact, Inc., an online marketing company. Mr. Capone earned his undergraduate degree from the State University of New York College at Potsdam and his M.S. in Computer Science from Clarkson University.


There are no transactions involving Mr. Capone and the Company that require disclosure under Item 404(a) of Regulation S-K. In addition, there are no arrangements or understandings between Mr. Capone and any other person pursuant to which he was selected to serve as an officer of the Company.


In addition, the Board also appointed Ira Smedra, an independent Class I director of the Board, to succeed Mr. Vashovsky as Chairman of the Board, effective upon the Effective Time.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.

99.1   Press release of DocGo Inc. dated November 7, 2022
104   Cover Page Interactive Data File (formatted as Inline XBRL)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


By: /s/ Andre Oberholzer  
  Name:  Andre Oberholzer  
  Title: Chief Financial Officer  


Date: November 7, 2022





Exhibit 99.1




DocGo Announces Strong Third Quarter 2022 Results


Q3 Revenue of $104.3 Million Up 22% Year-Over-Year; Company Raises Full-Year 2022 Revenue and Adjusted EBITDA Guidance


Co-founder and CEO Stan Vashovsky announces his retirement effective December 31st; DocGo President Anthony Capone named new CEO; Mr. Vashovsky will consult with the Company through 2023 to assist with the transition


Company to host investor conference call and webcast today, November 7th, at 5:00 pm ET


NEW YORK, NY, November 7, 2022 - DocGo Inc. (Nasdaq: DCGO), a leading provider of last-mile mobile health services, today announced financial and operating results for the third quarter ending September 30, 2022.


Third Quarter Financial Highlights


Total revenue increased to $104.3 million compared to $85.8 million in Q3 2021, an increase of 22%.


Gross margin improved to 31.7% compared to 30.0% in Q3 2021.


Net income increased to $2.5 million, compared to $0.8 million in Q3 2021, an increase of 213%. Excluding a one-time loss on the remeasurement of warrant liabilities in the third quarter of this year of $1.8 million, net income would have been $4.3 million.


Adjusted EBITDA1 increased to $8.4 million compared to $4.0 million in Q3 2021, an increase of 110%.


Mobile Health revenue was $76.6 million compared to $67.9 million in Q3 2021, an increase of 12.9% year over year.


Transportation Services revenue increased to $27.7 million compared to $17.9 million in Q3 2021, an increase of 55%.


The company estimates that Mass Covid testing-related revenues accounted for mid-single digits on a percentage basis of total revenue during the quarter, compared to approximately 35% of revenue in Q3 2021. The last Mass Covid testing contracts concluded in September of this year.


Nine-month revenues through September 30, 2022 increased to $331.7 million, compared to $197.4 million in the same period in 2021, an increase of 68%.


Nine-month net income through September 30, 2022 amounted to $23.6 million, compared to a net loss of $1.1 million in the nine months ended September 30, 2021, an improvement of $24.7 million.


Nine-month Adjusted EBITDA1 through September 30, 2022 increased to $34.5 million, compared to $7.8 million in the same period in 2021, an increase of 342%.


Total cash and cash equivalents at the end of the period were $179.4 million compared to $179.1 million at fiscal year end 2021.



1Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” below for additional information on this non-GAAP financial measure and a reconciliation to the most comparable GAAP measure.





Guidance Update for Fiscal 2022


Revenue guidance is increased to $430-$440 million, up from a previous range of $425-$435 million.


Adjusted EBITDA2 guidance is increased to $41-$46 million, up from a previous range of $40-$45 million.


Guidance increase is based on both continued organic growth and incremental M&A activities.


Select Corporate Highlights


Expanded its partnership with Gary and Mary West PACE (West PACE) to launch innovative remote patient monitoring (RPM) to enhance care for PACE participants aged 55 and older within the San Diego market.


Announced its mobile health services are now available to Cigna commercial customers in New York and New Jersey, beginning October 1, 2022.


Announced that its UK-based subsidiary, Ambulnz Community Partners, has been awarded three new contracts, continuing to drive growth in Greater Manchester while also expanding services in Lancashire and Merseyside.


Executed a new contract to provide mobile health services to Horizon Healthcare Services, Inc. (Horizon) members, covering commercial and Medicare members in New Jersey. The arrangement includes Braven Health, a joint venture between Horizon and New Jersey’s two largest health systems (Hackensack Meridian Health and RWJ Barnabas Health), that offers Medicare Advantage plans in N.J. The agreement allows DocGo to potentially reach an additional 3.8 million people.


Announced and completed the redemption of all outstanding warrants to purchase shares of DocGo’s common stock that were issued as part of the units sold in Motion’s initial public offering (IPO), and that remained outstanding at 5:00 p.m. New York City time on September 16, 2022.


DocGo was named as a National Association of Emergency Medical Technicians Training Center, for our commitment to developing and sustaining an exceptional EMS training program, and meeting all the requirements as established by the NAEMT.


Co-founder and Chief Executive Officer Stan Vashovsky will be retiring effective December 31st. Current DocGo President Anthony Capone has been named the company’s new CEO and Mr. Vashovsky will consult with the Company through 2023 to assist with the transition.


Stan Vashovsky, CEO of DocGo, commented, “I am extremely proud of what we have been able to accomplish as a company these past seven years, introducing an entirely novel way of delivering quality care that is beneficial to both patients and payers alike. We are very fortunate to have someone with Anthony’s skill set and track record to take the reigns as CEO next year, and I have every confidence in the continued growth and success of this company.”


Anthony Capone, President of DocGo, stated, “By nearly any measure, our performance during the third quarter was significant validation of our unique tech-enabled model and the unmet needs that we are addressing with our mobile health and transportation solutions. We continue to gain share in our key territories, both in the US and UK, while also entering new markets, and I believe we are very well positioned to maintain the momentum that we currently enjoy. We are in a very strong financial position, with $179.4 million of total cash and equivalents as of September 30th, plus the recently announced $90 million line of credit that we announced with Citi, which remains undrawn. I anticipate a strong finish to the year and a catalyst-rich 2023 driven by continued strong organic growth and possible opportunistic acquisitions that expand our offering or geographic reach.”





2Adjusted EBITDA is a non-GAAP financial measure. We have not reconciled Adjusted EBITDA outlook to the most comparable GAAP outlook because it is not possible to do so without unreasonable efforts due to the uncertainty and potential variability of reconciling items, which are dependent on future events and often outside of management’s control and which could be significant. Because such items cannot be reasonably predicted with the level of precision required, we are unable to provide outlook for the comparable GAAP measure (net income). Forward- looking estimates of Adjusted EBITDA are made in a manner consistent with the relevant definitions and assumptions noted herein.





Conference call and webcast


DocGo management will host a conference call and webcast to discuss the third quarter results today, November 7th at 5:00 pm ET. To access the conference call, please dial 1-855-327-6837 (U.S.) or 1-631-891-4304 (international). Reference conference ID 10020451.


The webcast can be accessed at https://viavid.webcasts.com/starthere.jsp?ei=1575375&tp_key=57a0cdd161 or under “Events” on the “Investors” section of the Company’s website, https://ir.docgo.com/.


A replay of the webcast will be archived on the Company’s investor relations page through November 14th, 2022 at approximately 5:00 pm ET.


About DocGo


DocGo is a leading provider of last-mile mobile health services. DocGo is disrupting the traditional four-wall healthcare system by providing care to patients where and when they need it. DocGo’s innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.


Forward-Looking Statements


This announcement contains forward-looking statements (including within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and Section 27A of the U.S. Securities Act of 1933, as amended) concerning DocGo. These statements include, but are not limited to, statements that address our expected future business and financial performance and statements about (i) our plans, objectives and intentions with respect to future operations, services and products, including our transition to non-COVID related services, geographic expansion, new and existing contracts, M&A activity, workforce growth, leadership transition, cash position and share repurchase program, (ii) our competitive position and opportunities, including our ability to realize the benefits from our operating model, and (iii) other statements identified by words such as “may”, “will”, “expect”, “intend”, “plan”, “potential”, “believe”, “seek”, “could”, “estimate”, “judgment”, “targeting”, “should”, “anticipate”, “predict” “project”, “aim”, “goal”, “outlook”, “guidance”, and similar words, phrases or expressions. These forward-looking statements are based on management’s current expectations and beliefs, as well as assumptions made by, and information currently available to, management, and current market trends and conditions. Forward-looking statements inherently involve risks and uncertainties, many of which are beyond our control, and which may cause actual results to differ materially from those contained in our forward-looking statements. Accordingly, you should not place undue reliance on such statements. Particular uncertainties that could materially affect current or future results include possible accounting adjustments made in the process of finalizing reported financial results; any risks associated with global economic conditions and concerns; the effects of global outbreaks of pandemics or contagious diseases or fear of such outbreaks, such as the COVID-19 coronavirus pandemic; competitive pressures; pricing declines; rates of growth in our target markets; our ability to improve gross margins; cost-containment measures; legislative and regulatory actions; the impact of legal proceedings and compliance risks; the impact on our business and reputation in the event of information technology system failures, network disruptions, cyber-attacks, or losses or unauthorized access to, or release of, confidential information; and the ability of the company to comply with laws and regulations regarding data privacy and protection. We undertake no intent or obligation to publicly update or revise any of these forward-looking statements, whether as a result of new information, future events or otherwise.





Non-GAAP Financial Measures


The following information provides definition and reconciliation of the non-GAAP financial measure presented in this earnings release to the most directly comparable financial measure calculated and presented in accordance with generally accepted accounting principles (GAAP). The company has provided this non-GAAP financial information, which is not calculated or presented in accordance with GAAP, as information supplemental and in addition to the financial measures presented in this earnings release that are calculated and presented in accordance with GAAP. Such non-GAAP financial measure should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measures presented in this earnings release. The non-GAAP financial measure in this earnings release may differ from similarly titled measures used by other companies.


Adjusted EBITDA


Adjusted EBITDA is considered a non-GAAP financial measure under the Securities and Exchange Commission’s (“SEC”) rules because it excludes certain amounts included in net income (loss) calculated in accordance with GAAP. Management believes that Adjusted EBITDA is a meaningful measure to share with investors because it facilitates comparison of the current period performance with that of the comparable prior period. In addition, Adjusted EBITDA affords investors a view of what management considers to be the Company’s core operating performance as well as the ability to make a more informed assessment of such operating performance as compared with that of the prior period.


The table below reflects the reconciliation of Net Income (Loss) to Adjusted EBITDA for the three and nine months ended September 30, 2022 compared to the same periods in 2021 (in millions):


   Q3   YTD 
   2021   2022   2021   2022 
Net Income/(loss) (GAAP)  $0.8   $2.5   $(1.1)  $23.6 
(+) Net Interest expense/ (income)  $0.2   $(0.3)  $0.5   $(0.3)
(+) Income Tax  $0.6   $0.4   $0.6   $1.2 
(+) Depreciation & amortization  $2.0   $3.0   $5.5   $7.3 
(+) Other (income)/expense  $0.0   $1.7   $0.0   $(2.7)
EBITDA  $3.6   $7.3   $5.5   $29.1 
(+) Non-cash stock compensation  $0.4   $1.1   $1.1   $4.6 
(+) Non-recurring expense  $0.0   $0.0   $1.2   $0.8 
Adjusted EBITDA  $4.0   $8.4   $7.8   $34.5 





DocGo Inc. and Subsidiaries



   September 30,   December 31, 
   2022   2021 
   Unaudited   Audited 
Current assets:        
Cash and cash equivalents  $169,598,749   $175,537,221 
Accounts receivable, net of allowance of $7,376,957 and $7,377,389 as of September 30, 2022 and December 31, 2021, respectively   79,999,764    78,383,614 
Prepaid expenses and other current assets   2,394,324    2,111,656 
Total current assets   251,992,837    256,032,491 
Property and equipment, net   17,577,830    12,733,889 
Intangibles, net   20,647,790    10,678,049 
Goodwill   34,533,363    8,686,966 
Restricted cash   9,753,575    3,568,509 
Operating lease right-of-use assets   8,185,547    4,195,682 
Finance lease right-of-use assets   9,421,196    9,307,113 
Equity method investment   712,718    589,058 
Other assets   3,095,354    3,810,895 
Total assets  $355,920,210   $309,602,652 
Current liabilities:          
Accounts payable  $12,153,337   $15,833,970 
Accrued liabilities   38,558,074    35,110,877 
Line of credit   1,025,881    25,881 
Notes payable, current   680,703    600,449 
Due to seller   9,802,238    1,571,419 
Contingent Consideration   4,000,000    0 
Operating lease liability, current   2,059,278    1,461,335 
Finance lease liability, current   2,858,968    3,271,990 
Total current liabilities   71,138,479    57,875,921 
Notes payable, non-current   1,456,105    1,302,839 
Operating lease liability, non-current   6,406,246    2,980,946 
Finance lease liability, non-current   6,086,521    6,867,420 
Warrant liabilities   -    13,518,502 
Total liabilities   85,087,351    82,545,628 
Commitments and Contingencies          
Class A common stock ($0.0001 par value; 500,000,000 shares authorized as of  September 30, 2022 and December 31,2021; 102,824,878 and 100,133,953 shares issued and outstanding as of September 30, 2022 and December 31,2021, respectively)   10,778    10,013 
Additional paid-in-capital   301,522,213    283,161,216 
Accumulated deficit   (37,036,937)   (63,556,714)
Accumulated other comprehensive loss   (276,213)   (32,501)
Total stockholders’ equity attributable to DocGo Inc. and Subsidiaries   264,219,841    219,582,014 
Noncontrolling interests   6,613,018    7,475,010 
Total stockholders’ equity   270,832,859    227,057,024 
Total liabilities and stockholders’ equity  $355,920,210   $309,602,652 





DocGo Inc. and Subsidiaries



   Three Months Ended
September 30,
   Nine Months Ended
September 30,
   2022   2021   2022   2021 
Revenue, net  $104,319,894   $85,838,988   $331,730,750   $197,394,379 
Cost of revenues (exclusive of depreciation and amortization, which is shown separately below)   71,254,838    60,025,728    219,418,873    137,080,202 
Operating expenses:                    
General and administrative   22,186,036    19,612,243    70,684,270    47,239,204 
Depreciation and amortization   3,014,864    2,019,576    7,253,656    5,514,303 
Legal and regulatory   2,200,964    813,204    6,610,223    2,646,573 
Technology and development   1,373,146    854,618    3,663,299    1,980,899 
Sales, advertising and marketing   90,856    994,401    2,348,917    3,029,182 
Total expenses   100,120,704    84,319,770    309,979,238    197,490,363 
Income (loss) from operations   4,199,190    1,519,218    21,751,512    (95,984)
Other income (expenses):                    
Interest income (expense), net   334,221    (255,711)   296,891    (500,849)
Gain/(loss) on remeasurement of warrant liabilities   (1,831,947)   -    1,137,070    - 
Gain/(loss) on initial equity method investments   93,371    -    99,840    - 
Gain/(loss) on remeasurement of finance leases   -    -    1,388,273    - 
Gain from PPP loan forgiveness   -    142,667    -    142,667 
Gain/(loss) on disposal of fixed assets   42,667    -    42,667    (27,730)
Other income/(expense)   30,900    -    42,288    - 
Total other income (expense)   (1,330,788)   (113,044)   3,007,029    (385,912)
Net income (loss) before income tax benefit (expense)   2,868,402    1,406,174    24,758,541    (481,896)
Income tax benefit (expense)   (401,916)   (604,608)   (1,163,755)   (613,531)
Net income (loss)   2,466,486    801,566    23,594,786    (1,095,427)
Net income (loss) attributable to noncontrolling interests   (687,944)   (2,705,954)   (2,924,992)   (1,278,363)
Net income (loss) attributable to stockholders of DocGo Inc. and Subsidiaries   3,154,430    3,507,520    26,519,778    182,936 
Other comprehensive income (loss)                    
Foreign currency translation adjustment   248,283    69,193    252,854    171,846 
Total comprehensive gain (loss)  $3,402,713   $3,576,713   $26,772,632   $354,782 
Net income (loss) per share attributable to DocGo Inc. and Subsidiaries - Basic  $0.03   $0.06   $0.26   $0.01 
Weighted-average shares outstanding - Basic   98,960,538    58,388,866    100,725,697    58,388,866 
Net income (loss) per share attributable to DocGo Inc. and Subsidiaries - Diluted  $0.03   $0.04   $0.24   $- 
Weighted-average shares outstanding - Diluted   107,403,135    83,701,783    109,168,293    83,701,783 





DocGo Inc. and Subsidiaries



   Nine Months Ended
September 30,
   2022   2021 
Net income (loss)  $23,594,786   $(1,095,427)
Adjustments to reconcile net income to net cash provided by operating activities:          
Depreciation of property and equipment   2,592,244    1,697,380 
Amortization of intangible assets   2,269,423    1,432,983 
Amortization of finance lease right-of-use assets   2,391,989    2,383,940 
(Gain) Loss on disposal of assets   (42,667)   27,730 
Gain from PPP loan forgiveness   -    (142,667)
Gain from equity method investment   (99,840)   - 
Bad debt expense   2,702,979    2,152,470 
Stock based compensation   4,616,056    1,224,580 
Gain on remeasurement of finance leases   (1,388,273)   - 
Gain on remeasurement of warrant liabilities   (1,137,070)   - 
Changes in operating assets and liabilities:          
Accounts receivable   2,894,650    (28,794,602)
Prepaid expenses and other current assets   (282,668)   (4,531,411)
Other assets   882,432    (1,786,407)
Accounts payable   (3,983,383)   9,422,628 
Accrued liabilities   2,596,887    24,861,804 
Net cash provided by operating activities   37,607,545    6,853,001 
Acquisition of property and equipment   (1,994,161)   (2,824,916)
Acquisition of intangibles   (1,956,434)   (1,571,959)
Acquisition of businesses   (33,843,373)   (56,496)
Proceeds from disposal of property and equipment   -    6,000 
Net cash used in investing activities   (37,793,968)   (4,447,371)
Proceeds from revolving credit line   1,000,000    8,000,000 
Repayments of notes payable   (585,711)   (374,456)
Due to seller   (1,007,800)   - 
Noncontrolling interest contributions   2,063,000    333,025 
Proceeds from exercise of stock options   1,880,568    - 
Common stock repurchased   (497,759)   - 
Equity costs   (19,570)   - 
Payments on obligations under finance lease   (2,146,857)   (1,830,823)
Net cash provided by financing activities   685,871    6,127,746 
Effect of exchange rate changes on cash and cash equivalents   (252,854)   171,846 
Net increase in cash and restricted cash   246,594    8,705,222 
Cash and restricted cash at beginning of period   179,105,730    34,457,273 
Cash and restricted cash at end of period  $179,352,324   $43,162,495 





DocGo Inc. and Subsidiaries



   Nine Months Ended
September 30,
   2022   2021 
Supplemental disclosure of cash and non-cash transactions:
Cash paid for interest  $102,203   $39,637 
Cash paid for interest on finance lease liabilities  $434,580   $381,937 
Cash paid for income taxes  $1,163,755   $613,531 
Right-of-use assets obtained in exchange for lease liabilities  $4,094,731   $3,569,276 
Fixed assets acquired in exchange for notes payable  $819,231   $271,194 
Acquisition of remaining 20% of Ambulnz UK LTD  $-   $228,518 
Gain from PPP loan forgiveness  $-   $142,667 
Share warrant conversion  $-   $- 
Reconciliation of cash and restricted cash          
Cash  $169,598,749   $39,550,926 
Restricted Cash   9,753,575    3,611,569 
Total cash and restricted cash shown in statement of cash flows  $179,352,324   $43,162,495 





  Three Months Ended
September 30,
   Nine Months Ended
September 30,
Revenue Breakdown   2022   2021   2022   2021 
Primary Geographical Markets                
United States  $101,337,899   $83,286,509   $322,706,143   $190,595,217 
United Kingdom   2,981,995    2,552,479    9,024,607    6,799,162 
Total revenue  $104,319,894   $85,838,988   $331,730,750   $197,394,379 
Major Segments/Service Lines                
Transportation Services  $27,670,109   $17,916,162   $77,657,852   $65,657,141 
Mobile Health   76,649,785    67,922,826    254,072,898    131,737,238 
Total revenue  $104,319,894   $85,838,988   $331,730,750   $197,394,379 









Malory Van Guilder
Skyya PR for DocGo

Mike Cole

Steve Halper
LifeSci Advisors